Se încarcă compania
Just reported
Q3 2026 results
From Beone Medicines's results release of 5 noiembrie 2026; its quarterly report has since been filed.
Revenue
Actual
1,89B USD
+34 % y/y
+11 % q/qGuided
—
No guide given
EPS, GAAP
Actual
3,25 USD
+213 % y/y
+56 % q/qGuided
—
No guide given
Operating income, GAAP
Actual
418,7M USD
+157 % y/y
+29 % q/qGuided
—
No guide given
Company outlook
Full year 2026
- Revenue6,9B USD – 7B USD+30 % y/y First given
- Operating income, adjusted1,9B USD – 2B USDFirst given
- Operating income, GAAP1,2B USD – 1,3B USD+180 % y/y First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Beone Medicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
EXELExelixis, Inc.17B USDA+
JAZZJazz Pharmaceuticals plc15,4B USDA
HALOHalozyme Therapeutics, Inc.11,5B USDA+
TECHBIO-Techne Corp11,4B USDA+
TGTXTG Therapeutics, Inc.9,8B USDA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
BIIBBiogen Inc.28 oct. 2026BAGraded B, now A
Cum face bani
- Sales of cancer medicines98 %
Ponderile din venituri sunt estimări pentru Q1 2026, nu cifre dintr-un raport depus.
Concurează cu
Ce vinde6
BRUKINSA (zanubrutinib)
A pill for several blood cancers that blocks Bruton tyrosine kinase, a protein that helps certain cancer cells grow.
TEVIMBRA (tislelizumab)
An antibody treatment that blocks a signal cancer cells use to reduce the immune system's attack on them.
BEQALZI (sonrotoclax)
A pill that blocks the B-cell lymphoma 2 protein, which can help cancer cells survive; it is approved in the United States for certain mantle cell lymphoma patients.
Afișează încă 3
XGEVA (denosumab)
An antibody medicine marketed by BeOne in China to help prevent bone complications in people with cancer and to treat giant cell tumor of bone.
BLINCYTO (blinatumomab)
A medicine marketed by BeOne in China for acute lymphoblastic leukemia that helps immune cells recognize and attack cancer cells.
KYPROLIS (carfilzomib)
A medicine marketed by BeOne in China for multiple myeloma that interferes with a process cancer cells use to dispose of unwanted proteins.
Cine cumpără2
- Commercial distributors and other medicine buyers purchase BeOne's products for sale or supply to treatment providers.
- Government health systems and private insurers decide which medicines they cover and reimburse; patients receive the medicines through their cancer care.
Pe ce se sprijină și ce l-ar putea dărâma
De ce depinde activitatea
- 1A large share of sales comes from BRUKINSA, so its continued use by doctors and patients and its coverage by health systems and insurers matter to revenue.
- 2Sales depend on government and private reimbursement, including coverage decisions and negotiated medicine prices in China and other markets.
- 3For licensed medicines such as XGEVA, BLINCYTO and KYPROLIS, BeOne depends on partner agreements and partner or contract manufacturers for supply.
- 4BeOne relies on some outside manufacturers, suppliers and research contractors for medicines, materials and development work.
Ce ar putea merge prost
- 1Clinical trials may not show that medicines work or are safe enough for regulators to approve them; delays, trial failures or safety problems could prevent new medicines or uses from reaching patients.
- 2Competition from medicines such as IMBRUVICA, CALQUENCE and KEYTRUDA, along with changes in coverage, reimbursement or medicine pricing, could reduce sales or patient access.
- 3BeOne operates across China, the United States and other markets, so changes in government policy, regulation or trade relations can affect approvals, manufacturing, sales and the movement of money.
Situațiile financiare complete →
Despre Beone Medicines Ltd.
BeOne Medicines discovers, develops, makes and sells treatments for cancer. Its main medicine, BRUKINSA (zanubrutinib), is a pill that blocks Bruton tyrosine kinase, a protein involved in some blood cancers. It also sells TEVIMBRA, an antibody that blocks a signal cancers use to dampen immune attacks, and markets licensed cancer medicines in China.
- Sediu
- Basel, Switzerland
- Înființată în
- 2010
- Angajați
- More than 12,000 (Q2 2026, medium)
- Listată la
- Nasdaq
- Sfârșitul exercițiului financiar
- December 31
Construit din raportările proprii ale Beone Medicines Ltd. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
